ArticleExperimental hematology & oncology2023

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients.

Yunju Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.